This Article Full Text (PDF) Erratum (v39,p1139) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rustum, Y. M. Articles by Preisler, H. D. Search for Related Content PubMed PubMed Citation Articles by Rustum, Y. M. Articles by Preisler, H. D.

Correlation between Leukemic Cell Retention of 1-ß-D-Arabinofuranosylcytosine 5'-Triphosphate and Response to Therapy¹

Departments of Medicine A [Y. M. R., H. D. P.] and Grace Cancer Drug Center [Y. M. R.], Roswell Park Memorial Institute, Buffalo, New York 14263

The relationship between the phosphorylation of 1-ß-D-arabinofuranosylcytosine (ara-C) and intracellular retention of 1-ß-D-arabinofuranosylcytosine triphosphate (ara-CTP) in vitro by leukemic myeloblasts and the response of patients to treatment with ara-C and anthracycline was studied. There were quantitative differences between patients in the amount of ara-CTP initially formed and that retained intracellularly at 4 hr. On the basis of these differences, the patients could be placed into 2 subgroups: those 13 patients whose leukemic cell retention was 36% and the remaining 15 patients whose leukemic cells retained 19% ara-CTP's. Of the 13 patients in the high-retention group, 11 attained complete remission. Seven of the 11 patients remain in complete remission at 55+ to 129+ weeks. Nine of 15 patients whose ara-CTP retention was 19% attained complete remission. Eight of these patients have relapsed between 11 and 92 weeks, with a single patient remaining in remission at 58+ weeks. The median remission duration for this group was 28 weeks, while for the high retention it has already exceeded 63 weeks.

These data indicate that, although these patients are clinically diagnosed as acute myelocytic leukemia and treated in an identical manner, their cells metabolize ara-C differently. The data demonstrate a significant correlation between ara-CTP formation and retention in vitro by acute myelocytic leukemia cells and the duration of remission of patients receiving ara-C as part of their remission induction and maintenance therapy.

¹ Supported in part by Project Grant CA-18420, Program Project Grant CA-21071, and Core Program Grants CA-5834 and CA-13038 from the National Cancer Institute.

² To whom requests for reprints should be addressed.

Received 6/ 5/78. Accepted 9/25/78.

This article has been cited by other articles:

				D. S. Shewach and T. S. Lawrence It's What's Inside That Counts J. Clin. Oncol., September 15, 2003; 21(18): 3383 - 3384. [Full Text] [PDF]

				F. X. Mahon, M. W. N. Deininger, B. Schultheis, J. Chabrol, J. Reiffers, J. M. Goldman, and J. V. Melo Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood, August 1, 2000; 96(3): 1070 - 1079. [Abstract] [Full Text] [PDF]

				Y. Y. Hon and W. E. Evans Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach Clin. Chem., February 1, 1998; 44(2): 388 - 400. [Abstract] [Full Text] [PDF]

				G. Jahns-Streubel, C. Reuter, U. Auf der Landwehr, M. Unterhalt, E. Schleyer, B. Wormann, T. Buchner, and W. Hiddemann Activity of Thymidine Kinase and of Polymerase alpha  as Well as Activity and Gene Expression of Deoxycytidine Deaminase in Leukemic Blasts Are Correlated With Clinical Response in the Setting of Granulocyte-Macrophage Colony-Stimulating Factor-Based Priming Before and During TAD-9 Induction Therapy in Acute Myeloid Leukemia Blood, September 1, 1997; 90(5): 1968 - 1976. [Abstract] [Full Text] [PDF]

				H. Iwasaki, P. Huang, M. J. Keating, and W. Plunkett Differential Incorporation of Ara-C, Gemcitabine, and Fludarabine Into Replicating and Repairing DNA in Proliferating Human Leukemia Cells Blood, July 1, 1997; 90(1): 270 - 278. [Abstract] [Full Text] [PDF]

				V. Skalski, K. R. Brown, B. Y. Choi, Z.-Y. Lin, and S. Chen A 3'-5' Exonuclease in Human Leukemia Cells. IMPLICATIONS FOR RESISTANCE TO 1-beta -D-ARABINOFURANOSYLCYTOSINE AND 9-beta -D-ARABINOFURANOSYL-2-FLUOROADENINE 5'-MONOPHOSPHATE J. Biol. Chem., August 11, 2000; 275(33): 25814 - 25819. [Abstract] [Full Text] [PDF]